➡ Upstream Target
alzheimer's disease
✗ KILL CRITERIA
- APOE4-to-APOE3 prime-editing fails to reduce amyloid or tau burden in homozygous APOE4 knock-in mice
- Mendelian randomization using APOE4-independent AD risk instruments finds no causal AD association
- APOE4 carriers treated with ASO show no reduction in CSF Aβ42/40 ratio vs. placebo at 18 months
Effect Size
2.2199999999999998